Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Indications:
BETMIRA ER 25MG is indicated for the treatment of overactive bladder (OAB) symptoms such as urgency, frequency, and urge incontinence.
Pharmacology:
BETMIRA ER contains Mirabegron, a beta-3 adrenergic agonist. It works by relaxing the detrusor muscle in the bladder, increasing its storage capacity and reducing urinary urgency and frequency.
Dosage and Administration:
-
Recommended dosage: 25 mg once daily, with or without food.
-
Dosage adjustment may be needed based on individual response and renal or hepatic function.
-
The tablet should be swallowed whole, not crushed or chewed.
Interaction:
-
CYP3A4 inhibitors (e.g., ketoconazole) may increase mirabegron plasma levels.
-
Concurrent use with anticholinergic drugs may enhance therapeutic effects but increase adverse reactions.
Contraindications:
-
Hypersensitivity to Mirabegron or any component of the formulation.
-
Severe uncontrolled hypertension.
Side Effects:
-
Common: Headache, dry mouth, dizziness, urinary tract infection.
-
Rare: Increased blood pressure, angioedema, or allergic reactions.
Pregnancy & Lactation:
-
Pregnancy: Use only if the potential benefit justifies the risk to the fetus.
-
Lactation: It is unknown whether Mirabegron is excreted in human milk. Exercise caution when administering to nursing mothers.
Precautions & Warnings:
-
Monitor blood pressure periodically, especially in patients with a history of hypertension.
-
Use with caution in patients with severe renal or hepatic impairment.
Therapeutic Class:
Beta-3 Adrenergic Receptor Agonist.
Storage Conditions:
-
Store below 25°C, protected from light and moisture.
-
Keep out of reach of children.
.jpg)
.jpg)
Change Language